SCHEMBL3601361

SCHEMBL3601361

Nc1ccc(-c2ccc3ccn(CC(=O)NCCNCC4CCCCC4)c3c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 5/20 0.44
HSD17B10 Q99714 5/20 0.44
TSHR P16473 5/20 0.44
HPGD P15428 4/20 0.44
POLB P06746 2/20 0.44
USP2 O75604 1/20 0.44
GRIN2B Q13224 5/20 0.43
LMNA P02545 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
NPY5R Q15761 2/20 0.38
FAAH O00519 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598451 0.91 ALDH1A1 (0.45) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3600543 0.90 KDM4E (0.46) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3597368 0.90 TSHR (0.46) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3600291 0.90 GRIN2B (0.55) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3602467 0.90 KDM4E (0.46) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3610563 0.90 NPY5R (0.44) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3591120 0.89 KDM4E (0.47) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3598919 0.89 HTR6 (0.47) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3604146 0.89 KDM4E (0.45) KDM4EALDH1A1HSD17B10TSHRHPGD
SCHEMBL3591928 0.89 GRIN2B (0.46) KDM4EALDH1A1HSD17B10TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 KDM4E 4801/4885ALDH1A1 662/4885HSD17B10 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.